ArticleNature communications2018
Heterogeneity in tumor chromatin-doxorubicin binding revealed by in vivo fluorescence lifetime imaging confocal endomicroscopy.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Metabolic profiling of steatotic liver disease by fluorescence lifetime imaging microscopy.Communications medicine · 2026Article
- Mesoscopic Fluorescence Imaging of Light-Triggered Chemotherapeutic Release in Cancer Spheroid Models.Pharmaceutics · 2026Article
- HSP90AA1-VDAC1 interaction contributes to breast cancer progression and doxorubicin resistance through PI3K/AKT signaling.Breast cancer research : BCR · 2026Article
- Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review.Frontiers in pharmacology · 2026Review
- High-speed fluorescence lifetime imaging microscopy: techniques, applications, and prospects.Biophotonics discovery · 2025Review
- Label-free metabolic fingerprinting of motile mammalian spermatozoa with subcellular resolution.BMC biology · 2025Article
- Motion Compensation in Pulmonary Fluorescence Lifetime Imaging: An Image Processing Pipeline for Artefact Reduction and Clinical Precision.IEEE open journal of engineering in medicine and biology · 2025Article
- High-throughput fluorescence lifetime imaging flow cytometry.Nature communications · 2024Article
- Surgical polarimetric endoscopy for the detection of laryngeal cancer.Nature biomedical engineering · 2023Article
- Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time.Frontiers in immunology · 2023Review
- Effect of Collagen Matrix on Doxorubicin Distribution and Cancer Cells' Response to Treatment in 3D Tumor Model.Cancers · 2022Article
- NAD(P)H fluorescence lifetime imaging of live intestinal nematodes reveals metabolic crosstalk between parasite and host.Scientific reports · 2022Article
- A guide for single-particle chromatin tracking in live cell nuclei.Cell biology international · 2022Review
- Multiphoton intravital microscopy of rodents.Nature reviews. Methods primers · 2022Article
- Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures.Genome medicine · 2021Article
- Fluorescence lifetime imaging for studying DNA compaction and gene activities.Light, science & applications · 2021Article
- Luminescence lifetime imaging of three-dimensional biological objects.Journal of cell science · 2021Article
- Contribution of advanced fluorescence nano microscopy towards revealing mitotic chromosome structure.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2021Review
- Review
- Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
We present an approach to quantify drug-target engagement using in vivo fluorescence endomicroscopy, validated with in vitro measurements. Doxorubicin binding to chromatin changes the fluorescence lifetime of histone-GFP fusions that we measure in vivo at single-cell resolution using a confocal laparo/endomicroscope. We measure both intra- and inter-tumor heterogeneity in doxorubicin chromatin engagement in a model of peritoneal metastasis of ovarian cancer, revealing striking variation in the efficacy of doxorubicin-chromatin binding depending on intra-peritoneal or intravenous delivery. Further, we observe significant variations in doxorubicin-chromatin binding between different metastases in the same mouse and between different regions of the same metastasis. The quantitative nature of fluorescence lifetime imaging enables direct comparison of drug-target engagement for different drug delivery routes and between in vitro and in vivo experiments. This uncovers different rates of cell killing for the same level of doxorubicin binding in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.